Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533702 · ClinicalTrials.gov registry record · Phase 2
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00533702 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 106 participants.
The verdict
NCT00533702, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.
Interventions
- DRUG Dacarbazine
- BIOLOGICAL IMC-1121B (ramucirumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00533702
The ClinicalTrials.gov registry entry for NCT00533702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dacarbazine is the first listed.
NCT00533702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00533702 about?
NCT00533702 is a clinical study titled "A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma". The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.
What is the current status of trial NCT00533702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2007-11. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00533702?
The interventions under investigation include: Dacarbazine (DRUG), IMC-1121B (ramucirumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00533702?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.